Flexion Therapeutics (FLXN) saw its loss widen to $23.88 million, or $0.75 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $16.82 million, or $0.78 a share. The company has not recorded any revenues for the current as well as previous quarter.
Operating loss for the quarter was $23.78 million, compared with an operating loss of $16.67 million in the previous year period.
"The first few months of 2017 marked another period of impressive growth for Flexion," commented Michael Clayman, M.D., president and chief executive officer. "We continued to attract top talent, made great progress building our commercial infrastructure, strengthened the IP estate for Zilretta and significantly advanced our launch plans. Furthermore, following our recent convertible debt offering, we believe we now have the capital to take us well into 2019, more than one year after the anticipated launch of Zilretta. We are excited about Flexion’s future and the potential to make a meaningful difference for the millions of patients confronting OA."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]